Mepolizumab (Nucala®, GlaxoSmithKline) for Asthma
The California Endowment, Oakland, CA
The California Technology Assessment Forum (CTAF), a core program of the Institute for Clinical and Economic Review (ICER), held a public meeting in February 2016 to discuss a drug for patients with severe eosinophilic asthma. The asthma drug, mepolizumab (Nucala®, GlaxoSmithKline), is a once-monthly injectable monoclonal antibody against interleukin-5 (IL-5).
Public comments received on the Draft Evidence Report.